SCHEMBL4511804

SCHEMBL4511804

Cc1cc(Nc2nc(N3CC4(CCNCC4)C3)nc3ncccc23)[nH]n1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.44
▸ HSD17B10 Q99714 4/20 0.44
▸ HPGD P15428 2/20 0.44
▸ CYP1A2 P05177 3/20 0.38
▸ PRKCQ Q04759 2/20 0.37
▸ PRKCD Q05655 2/20 0.37
▸ PLK4 O00444 1/20 0.37
▸ PAK4 O96013 1/20 0.37
▸ HTR2A P28223 5/20 0.36
▸ PRKCA P17252 1/20 0.36
▸ CYP2D6 P10635 3/20 0.35
▸ SRC P12931 2/20 0.35
▸ CCR4 P51679 3/20 0.34
▸ CYP3A4 P08684 2/20 0.33
▸ TSHR P16473 2/20 0.33
▸ USP2 O75604 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ ABCG2 Q9UNQ0 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4533134 0.87 HSD17B10 (0.48) ALDH1A1HSD17B10HPGDCYP1A2CYP2D6
SCHEMBL4526646 0.86 HSD17B10 (0.44) ALDH1A1HSD17B10HPGDCYP1A2CYP2D6
SCHEMBL13633931 0.85 PAK4 (0.52) ALDH1A1HSD17B10HPGDPLK4PAK4
SCHEMBL4529942 0.83 PAK4 (0.39) HSD17B10PRKCQPRKCDPLK4PAK4
SCHEMBL5314611 0.83 PAK4 (0.34) PRKCQPRKCDPLK4PAK4HTR2A
SCHEMBL4512984 0.82 HSD17B10 (0.49) ALDH1A1HSD17B10HPGDCYP1A2CYP2D6
SCHEMBL4535745 0.82 ACACB (0.41) ALDH1A1HSD17B10HPGDCYP1A2CYP2D6
SCHEMBL4531067 0.79 PAK4 (0.37) PRKCQPRKCDPAK4PRKCACCR4
SCHEMBL4521530 0.78 CCR4 (0.36) PRKCQPRKCDPAK4PRKCACCR4
SCHEMBL4519095 0.77 HSD17B10 (0.41) ALDH1A1HSD17B10HPGDCYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090281073-A1 HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS BHATTACHARYA SAMIT KUMAR 2009-11-12 — — US disclosed
EP-1831216-A2 HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS Pfizer Products Inc. (US) 2007-09-12 — — EP disclosed
WO-2006067614-A2 HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER PRODUCTS INC. (US) 2006-06-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281073-A1 HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS CCNY, TP53, CCNE1 ALDH1A1 772/4885HSD17B10 944/4885HPGD 1017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback